Gaudium IVF shares list at 5% premium over IPO price on BSE, NSE

Gaudium IVF and Women Health listed at a 5% premium over its IPO price, despite a flat GMP. The IPO saw strong retail and NII demand, and proceeds will fund new IVF centres and loan repayment.The IPO, which closed on February 24, was subscribed 7....

ETMarkets.com
Gaudium IVF and Women Health debuted on the stock market at a 5% premium, opening at Rs 83 against its IPO price of Rs 79.
Shares of Gaudium IVF and Women Health made their stock market debut on Friday, February 27, listing at a 5% premium over the IPO price. The stock opened at Rs 83 apiece on both BSE and NSE against the issue price of Rs 79. The listing was higher than GMP expectations, which had suggested a flat opening. Shares of the company were seen trading at a 0% premium ahead of the debut.

The IPO, which closed on February 24, was subscribed 7.27 times overall. The retail category was subscribed 7.60 times, while the NII portion saw strong demand at 14.05 times. The QIB (excluding anchor) portion was subscribed 1.62 times.

The company plans to utilise Rs 50 crore towards setting up new IVF centres, Rs 20 crore towards repayment or prepayment of certain loans and the balance towards general corporate purposes.


Gaudium IVF operates a fertility clinic chain across India using a hub-and-spoke model. The company runs more than 30 locations, including seven hubs and 28 spokes, and has centres in Delhi, Mumbai, Bangalore, Patna, Ludhiana and Srinagar.

It offers IVF, ICSI, IUI, ovulation induction, male infertility treatments and high-risk pregnancy management services. The company also caters to international patients from countries such as the US, UK, Canada, Kenya, South Africa and Oman, tapping into medical tourism demand.

On the financial front, for FY25 the company reported total income of Rs 70.96 crore and PAT of Rs 19.13 crore. EBITDA stood at Rs 28.63 crore, translating into an EBITDA margin of 40.48%. For the six months ended September 30, 2025, total income was Rs 49.75 crore and PAT was Rs 12.51 crore.
ADVERTISEMENT

With GMP flat at 0% despite healthy subscription, listing gains appear limited for now. Market participants will watch whether strong NII and retail participation translates into stable demand on debut or whether the stock lists near the issue price amid cautious broader market sentiment.
ADVERTISEMENT
READ MORE

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Markets › Stocks › News › Gaudium IVF shares list at 5% premium over IPO price on BSE, NSE
Text Size:AAA
Success
This article has been saved

*

+